Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology
27 avr. 2023 07h30 HE
|
Zai Lab Limited
SHANGHAI, China and CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a strategic partnership and exclusive worldwide license agreement...
Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
26 avr. 2023 10h25 HE
|
Zai Lab Limited
SHANGHAI and CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that the results of the LUNAR phase 3 clinical trial in metastatic,...
Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
20 avr. 2023 07h30 HE
|
Zai Lab Limited
SHANGHAI, China and CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the first quarter of...
Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting
11 avr. 2023 08h03 HE
|
Zai Lab Limited
SHANGHAI and CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data including a translational and biomarker data analysis from its...
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
20 mars 2023 06h35 HE
|
Zai Lab Limited
Third positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p<0.0001) KarXT was generally well...
Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
01 mars 2023 16h01 HE
|
Zai Lab Limited
Total revenue of $215.0 million for 2022, representing a 49.0% increase y-o-y; ZEJULA® achieved 55.2% y-o-y growthStrong balance sheet with a cash position of $1.0 billion as of December 31,...
Zai Lab Announces Participation in March Investor Conferences
28 févr. 2023 07h30 HE
|
Zai Lab Limited
SHANGHAI and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that members of the company’s senior management team will participate in...
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
22 févr. 2023 16h30 HE
|
Zai Lab Limited
SHANGHAI, China and CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present two oral presentations highlighting the ad hoc interim overall...
Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
22 févr. 2023 07h30 HE
|
Zai Lab Limited
SHANGHAI and CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has...
Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
09 févr. 2023 07h30 HE
|
Zai Lab Limited
SHANGHAI and CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that it will report financial results and corporate updates for the...